



中国病原生物学杂志

ZHONGGUO BINGYUAN SHENGWUXUE ZAZHI

2023年3月第18卷第3期

(总第195期)

Mar. 2023 Vol. 18, No. 3

国家卫生健康委员会 主管
中华预防医学会 主办
山东省寄生虫病防治研究所



JOURNAL OF PATHOGEN BIOLOGY

中文核心期刊(基础医学类)
中国科学引文数据库(CSCD)来源期刊
中国科技核心期刊
中国生物医学类核心期刊
RCCSE中国核心学术期刊
科技期刊世界影响力指数(WJCI)报告收录期刊
中国科技论文统计源期刊
《中国学术期刊综合评价数据库》来源期刊
《中国核心期刊(遴选)数据库》收录期刊

ISSN 1673-5234



中华预防医学会系列杂志
SERIAL JOURNAL OF CHINESE PREVENTIVE MEDICINE ASSOCIATION

3
2023

中国病原生物学杂志

二〇二三年三月

第十八卷

第三期

中华预防医学会系列杂志

Res,2020(157):104820.

[52] Zhang Y,Gu X,Zhou Y,et al. An integrative analysis of Qingfei Paidu Decoction for its anti-HCoV-229E mechanism in cold and damp environment based on the pharmacokinetics,metabolomics and molecular docking technology [J]. Phytomedicine, 2022 (108):154527.

[53] 赵静,田赛赛,杨健,等. 清肺排毒汤治疗新型冠状病毒肺炎机制的网络药理学探讨 [J]. 中草药,2020,51(4):829-835.

[54] 沈爱明,张伟,吴卓,等. 清肺排毒汤治疗新型冠状病毒肺炎的中医理论分析 [J]. 辽宁中医杂志,2020,47(3):106-108.

[55] Ren JL,Zhang AH,Wang XJ. Traditional Chinese medicine for COVID-19 treatment [J]. Pharmacol Res,2020(155):104743.

[56] Cao P,Wu S,Wu T,et al. The important role of polysaccharides from a traditional Chinese medicine-Lung Cleansing and Detoxifying Decoction against the COVID-19 pandemic [J]. Carbohydr Polym,2020(240):116346.

[57] Huang F,Li Y,Leung EL,et al. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19) [J]. Pharmacol Res,2020(158):104929.

[58] Liu Z,Li X,Gou C,et al. Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients [J]. J Tradit Chin Med,2020,40(3):467-472.

[59] 彭文潘,徐冰,韩迪,等. 基于网络药理学和分子对接探究金花清感颗粒治疗新型冠状病毒肺炎的作用机制 [J]. 天然产物研究与开发,2020,32(12):1992-2002.

[60] Zhang Y,Yao YF,Yang YF,et al. Investigation of anti-SARS, MERS,and COVID-19 effect of Jinhua Qinggan Granules based on a network pharmacology and molecular docking approach [J]. Nat Prod Commun,2021,16(5):529-539.

[61] Wang Z,Zhang J,Zhan J,et al. Screening out anti-inflammatory or anti-viral targets in Xuanfei Baidu Tang through a new technique of reverse finding target [J]. Bioorg Chem, 2021 (116):105274.

[62] 冯利民,刘晓亚,张磊. 宣肺败毒颗粒治疗新型冠状病毒肺炎(奥密克戎)的临床疗效观察 [J]. 天津中医药,2022,39(5):545-550.

[63] Song S,Peng H,Wang Q,et al. Inhibitory activities of marine sulfated polysaccharides against SARS-CoV-2 [J]. Food Funct, 2020,11(9):7415-7420.

[64] Kwon PS,Oh H,Kwon SJ,et al. Sulfated polysaccharides

effectively inhibit SARS-CoV-2 in vitro [J]. Cell Discov,2020,6 (1):50.

[65] Jang Y,Shin H,Lee MK,et al. Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2 [J]. Sci Rep. 2021,11(1): 821.

[66] Ho TY,Wu SL,Chen JC,et al. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction [J]. Antiviral Res,2007,74(2):92-101.

[67] Muhseen ZT,Hameed AR,Al-Hasani HMH,et al. Promising terpenes as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor; Integrated computational approach [J]. J Mol Liq,2020(320):114493.

[68] Zhang L,Lin D,Sun X,et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α -ketoamide inhibitors [J]. Science,2020,368(6489):409-412.

[69] Maiti BK. Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication? [J]. ACS Pharmacol Transl Sci, 2020, 3 (5): 1017-1019.

[70] Steuten K, Kim H, Widen JC, et al. Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19 [J]. ACS Infect Dis, 2021, 7(6): 1457-1468.

[71] Swaim CD, Dwivedi V, Perng YC, et al. 6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro [J]. iScience, 2021, 24(10): 103213.

[72] Tian L, Qiang T, Liang C, et al. RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic [J]. Eur J Med Chem, 2021(213):113201.

[73] Ahmad M,Dwivedy A,Mariadasse R,et al. Prediction of Small Molecule Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus-2 RNA-dependent RNA Polymerase [J]. ACS Omega,2020,5(29):18356-18366.

[74] 何黎黎,龚普阳,封玥,等. 中药在抗新型冠状病毒肺炎(COVID-19)引起的细胞因子风暴中的应用分析 [J]. 中草药,2020,51 (6):1375-1385.

[75] 孙倩,于小勇. 中医药治疗新型冠状病毒肺炎述评 [J]. 河南中医,2020,40(7):983-986.

【收稿日期】 2022-10-17 【修回日期】 2023-01-03

(上接 368 页)

[60] Manning AJ, Kuehn MJ. Functional advantages conferred by extracellular prokaryotic membrane vesicles [J]. J Mol Microbiol Biotechnol,2013,23(1-2):131-141.

[61] Solanki KS, Varshney R, Qureshi S, et al. Non-infectious outer membrane vesicles derived from *Brucella abortus* S19 Δ per as an alternative acellular vaccine protects mice against virulent challenge[J]. Int Immunopharmacol,2021(90):107148.

[62] Acevedo R, Fernandez S, Zavas C, et al. Bacteria I outer membrane vesicles and vaccine applications[J]. Front Immunol, 2014,5(121):2-6.

[63] Eric D, Ahide L, NeetaJ, et al. Characterization of outer membrane vesicles from *Brucella melitensis* and protection induced in mice[J]. Clin Dev Immunol,2011,2012(2):1-13.

[64] Neeta JG, Araceli CR, Ramesh V, et al. Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against *Brucella melitensis* challenge in mice [J]. FEMSimmunol Med Microbiol,2012,66(3):436-444.

[65] 张瑞安. 粗糙型布鲁氏菌菌壳的制备及其免疫学特性研究[D]. 长春:吉林农业大学,2013.

[66] Karevan G, Ahmadi K, Taheri RA. et al. Immunogenicity of glycine nanoparticles containing a chimeric antigen as *Brucella* vaccine candidate[J]. Clin Exp Vaccine Res, 2021,10(1):35-43.

【收稿日期】 2022-10-13 【修回日期】 2022-01-06



中国学术期刊影响因子年报

Annual Report for Chinese Academic Journals Impact Factors

统计刊源证书

《中国病原生物学杂志》编辑部

经过多项学术指标综合评定，贵刊入选

2022《中国学术期刊影响因子年报》统计源期刊。

特颁发此证书！

证书编号：LY 2022-ZISC

证书有效期：2023年10月

《中国学术期刊(光盘版)》电子杂志社有限公司

中国科学文献计量评价研究中心

2022年10月9日



[18] Yu S, Zhu Y, Xu J, et al. Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2 [J]. *Phytomedicine*, 2021, 85: 153364.

[19] Luo W, Ding R, Guo X, et al. Clinical data mining reveals Gancao-Banxia as a potential herbal pair against moderate COVID-19 by dual binding to IL-6/STAT3 [J]. *Comput Biol Med*, 2022(145): 105457.

[20] 吕巧莉, 涂国刚, 王嘉琦, 等. 穿心莲内酯的研究进展及临床应用 [J]. *南昌大学学报(医学版)*, 2013, 53(1): 83-86.

[21] 张愿, 谢红艳, 田苑, 等. 基于网络药理学探讨穿心莲治疗新型冠状病毒肺炎机制研究 [J]. *四川中医*, 2021, 39(9): 56-61.

[22] Wang ZL, Wang S, Kuang Y, et al. A comprehensive review on phytochemistry, pharmacology, and flavonoid biosynthesis of *Scutellaria baicalensis* [J]. *Pharm Biol*, 2018, 56(1): 465-484.

[23] Liu H, Ye F, Sun Q, et al. *Scutellaria baicalensis* extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease invitro [J]. *J Enzyme Inhib Med Chem*, 2021, 36(1): 497-503.

[24] Lin H, Zhou J, Lin K, et al. Efficacy of *Scutellaria baicalensis* for the treatment of Hand, Foot, and Mouth Disease associated with encephalitis in patients infected with EV71: A multicenter, retrospective analysis [J]. *Biomed Res Int*, 2016 (2016): 5697571.

[25] 梁明辉. 中药虎杖的研究进展 [J]. *中国医药指南*, 2019, 17(10): 47-54.

[26] Xu H, Li J, Song S, et al. Effective inhibition of coronavirus replication by *Polygonum cuspidatum* [J]. *Front Biosci*, 2021, 26(10): 789-798.

[27] Sydiskis RJ, Owen DG, Lohr JL, et al. Inactivation of enveloped viruses by anthraquinones extracted from plants [J]. *Antimicrob Agents Chemother*, 1991, 35(12): 2463-2466.

[28] Pan B, Fang S, Zhang J, et al. Chinese herbal compounds against SARS-CoV-2: Puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor [J]. *Comput Struct Biotechnol J*, 2020(18): 3518-3527.

[29] 宗阳, 姚卫峰, 居文政. 以白介素6为受体挖掘中药单体治疗新型冠状病毒肺炎引发的细胞因子风暴的干预作用 [J]. *中国医院药学杂志*, 2020, 40(11): 1182-1188.

[30] 王桂芬. 中药黄芪的药理作用及临床应用效果观察 [J]. *临床医药文献电子杂志*, 2017, 4(16): 3115-3116.

[31] 邓晓霞, 李清宋, 陈中, 等. 黄芪抗肿瘤作用机制的研究进展 [J]. *中药新药与临床药理*, 2016, 27(02): 307-312.

[32] Min JS, Kim DE, Jin YH, et al. Kurarionone inhibits HCoV-OC43 infection by impairing the virus-induced autophagic flux in MRC-5 human lung cells [J]. *J Clin Med*, 2020, 9(7): 2230.

[33] Ma Q, Li R, Pan W, et al. Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF- κ B) signaling pathway [J]. *Phytomedicine*, 2020(78): 153296.

[34] Zhang BM, Wang ZB, Xin P, et al. Phytochemistry and pharmacology of genus *Ephedra* [J]. *Chin J Nat Med*, 2018, 16(11): 811-828.

[35] 周政, 朱春胜, 张冰. 基于数据挖掘的中医药治疗新型冠状病毒肺炎用药规律研究 [J]. *中国中药杂志*, 2020, 45(6): 1248-1252.

[36] Li X, Qiu Q, Li M, et al. Chemical composition and pharmacological mechanism of ephedra-glycyrrhiza drug pair against coronavirus disease 2019 (COVID-19) [J]. *Aging (Albany NY)*, 13(4): 4811-4830.

[37] 赵杰. 麻黄类药物对组成规律的基础研究—麻黄—甘草药对 [D]. 广州: 南方医科大学. 2012.

[38] Jia W, Wang C, Wang Y, et al. Qualitative and quantitative analysis of the major constituents in Chinese medical preparation Lianhua-Qingwen capsule by UPLC-DAD-QTOF-MS [J]. *ScientificWorldJournal*, 2015(2015): 731765.

[39] Hsieh CF, Lo CW, Liu CH, et al. Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus [J]. *J Ethnopharmacol*, 2012, 143(1): 57-67.

[40] Zhong Y, Zhou J, Liang N, et al. Effect of maxing shigan tang on H1N1 influenza A virus-associated acute lung injury in mice [J]. *Intervirology*, 2016, 59(5-6): 267-274.

[41] 丁新佩. 连花清瘟药物抗流感病毒的药理分析 [J]. *临床合理用药杂志*, 2012, 5(28): 32.

[42] Li H, Yang L, Liu FF, et al. Overview of therapeutic drug research for COVID-19 in China [J]. *Acta Pharmacol Sin*, 2020, 41(9): 1133-1140.

[43] Zeng M, Li L, Wu Z. Traditional Chinese medicine Lianhua Qingwen treating corona virus disease 2019 (COVID-19): Meta-analysis of randomized controlled trials [J]. *PLoS One*, 2020, 15(9): e0238828.

[44] Li RF, Hou YL, Huang JC, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [J]. *Pharmacol Res*, 2020(156): 104761.

[45] 牛明, 王睿林, 王仲霞, 等. 基于临床经验和分子对接技术的抗新型冠状病毒中医组方快速筛选模式及应用 [J]. *中国中药杂志*, 2020, 45(6): 1213-1218.

[46] Ho TY, Wu SL, Chen JC, et al. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction [J]. *Antiviral Res*, 2007, 74(2): 92-101.

[47] 凌晓颖, 陶嘉磊, 孙逊, 等. 基于网络药理学的连花清瘟方抗冠状病毒的物质基础及机制探讨 [J]. *中草药*, 2020, 51(7): 1723-1730.

[48] Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial [J]. *Phytomedicine*, 2021 (85): 153242.

[49] Hu K, Guan W, Bi Y, et al. Efficacy and safety of Lianhua Qingwen capsules, a repurposed Chinese herb, in patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial [Phytomedicine 85 (2021) 153242] [J]. *Phytomedicine*, 2022(94): 153800.

[50] Chen J, Wang YK, Gao Y, et al. Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming [J]. *BiomedPharmacother*, 2020(129): 110281.

[51] Yang R, Liu H, Bai C, et al. Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study [J]. *Pharmacol*